InsiderDB
Sign inStart free trial

Sen. John Boozman sold Gilead Sciences (GILD)

Sen. John Boozman (R-AR) · $1K–$15K · traded Apr 16, 2025

Transaction
Sold (full)
Amount
$1K–$15K
Owner
Joint
Traded
Apr 16, 2025
Disclosed
May 14, 2025
Days to disclose
28
Asset type
Stock
As filed
Gilead Sciences Inc
Industry
Drug Manufacturers - General · Healthcare
Official filing ↗All of Boozman's tradesAll Congress trades in GILD

Other trades in this filing

Recent Congress trades in GILD

Company context for GILD

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. GILDFinancial report·SEC EDGAR

    GILD: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 29, 2026, 8:09 PM EDTEvent / period: Sep 30, 2026Original source ↗
  2. GILDCompany announcement·SEC EDGAR

    GILD: Financial results

    Filed 8-K for an event or period dated 2026-10-29. Financial results.

    Public: Oct 29, 2026, 4:03 PM EDTEvent / period: Oct 29, 2026Original source ↗
  3. GILDLobbying report·Lobbying disclosures

    GILD: third_quarter 2026 lobbying report

    Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Advocate on drug pricing proposals. Proposals to exp

    Public: Oct 21, 2026, 1:36 PM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.